Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient received first dose of Vivotif on 02-Aug-2024 and second dose on 03-Aug-2024, consecutively in two days; Case reference number US-BN-2024-002310 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV24-1871) on 05-Aug-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication details were not provided. On 02-Aug-2024, the patient took the first dose of Vivotif (batch number: unknown), one capsule, via orally, as reported for travel. On 03-Aug-2024, one day after the first dose, the patient took the second dose of Vivotif (batch number: unknown), one capsule, via orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240805-20a7fd to US-BAVARIAN NORDIC A/S-US-BN-2024-002310, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unknown age took the second dose of Vivotif (one day after the first dose), one capsule, via orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unknown age took the second dose of Vivotif (one day after the first dose), one capsule, via orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.